Rapport Therapeutics, Inc. (RAPP)
30.65
+0.80
(+2.68%)
USD |
NASDAQ |
Oct 09, 16:00
30.74
+0.09
(+0.29%)
After-Hours: 20:00
Rapport Therapeutics Enterprise Value : 1.044B for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 1.044B |
| October 08, 2026 | 1.005B |
| October 07, 2026 | 1.054B |
| October 06, 2026 | 1.068B |
| October 05, 2026 | 1.118B |
| October 02, 2026 | 1.117B |
| October 01, 2026 | 1.148B |
| September 30, 2026 | 1.185B |
| September 29, 2026 | 1.157B |
| September 28, 2026 | 1.178B |
| September 25, 2026 | 1.200B |
| September 24, 2026 | 1.196B |
| September 23, 2026 | 1.211B |
| September 22, 2026 | 1.563B |
| September 21, 2026 | 1.476B |
| September 18, 2026 | 1.514B |
| September 17, 2026 | 1.586B |
| September 16, 2026 | 1.559B |
| September 15, 2026 | 1.621B |
| September 14, 2026 | 1.684B |
| September 11, 2026 | 1.666B |
| September 10, 2026 | 1.658B |
| September 09, 2026 | 1.678B |
| September 08, 2026 | 1.784B |
| September 04, 2026 | 1.769B |
| Date | Value |
|---|---|
| September 03, 2026 | 1.859B |
| September 02, 2026 | 1.909B |
| September 01, 2026 | 1.903B |
| August 31, 2026 | 1.908B |
| August 28, 2026 | 1.913B |
| August 27, 2026 | 2.011B |
| August 26, 2026 | 2.092B |
| August 25, 2026 | 2.028B |
| August 24, 2026 | 1.940B |
| August 21, 2026 | 1.887B |
| August 20, 2026 | 1.869B |
| August 19, 2026 | 1.927B |
| August 18, 2026 | 1.924B |
| August 17, 2026 | 1.896B |
| August 14, 2026 | 1.848B |
| August 13, 2026 | 1.845B |
| August 12, 2026 | 1.863B |
| August 11, 2026 | 1.915B |
| August 10, 2026 | 1.827B |
| August 07, 2026 | 1.755B |
| August 06, 2026 | 1.797B |
| August 05, 2026 | 1.609B |
| August 04, 2026 | 1.598B |
| August 03, 2026 | 1.530B |
| July 31, 2026 | 1.539B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.932B |
| Corcept Therapeutics, Inc. | 12.78B |
| Veru, Inc. | 18.84M |
| Johnson & Johnson | 657.89B |
| Eli Lilly & Co. | 1.156T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -56.62M |
| Total Expenses (Quarterly) | 56.62M |
| EPS Diluted (Quarterly) | -1.193 |
| Earnings Yield | -9.92% |
| Normalized Earnings Yield | -9.923 |